Yazılar

IBM Launches Power11 Chips and Servers to Simplify AI Deployment in Business

/in /tarafından

IBM has unveiled its latest data center innovation with the launch of the Power11 chips and accompanying server systems, targeting more energy-efficient performance and streamlined AI adoption for enterprise use. This marks IBM’s first major update to its Power chip line since 2020.

Designed to compete with Intel and AMD in data centers—especially in sectors like financial services, manufacturing, and healthcare—IBM’s Power11 systems integrate tightly coupled chips and software to enhance reliability and security.

Tom McPherson, IBM’s Power Systems general manager, highlighted the new systems’ operational resilience: available from July 25, the Power11 servers require no planned downtime for software updates, and average unplanned downtime is just over 30 seconds annually. Crucially, the systems can detect and respond to ransomware attacks within one minute.

Later this year, IBM plans to integrate the Power11 chips with Spyre, its AI accelerator chip launched last year. Unlike Nvidia’s focus on AI training, IBM’s approach centers on simplifying AI inference—the practical deployment of AI to accelerate business tasks.

McPherson explained that IBM aims to offer seamless AI inferencing capabilities that improve business processes without the high computational power needed for AI training. Early customers are already working with IBM to integrate these AI functions.

This new line reflects IBM’s strategy to provide businesses with secure, efficient, and easy-to-deploy AI solutions, emphasizing inference acceleration over raw training performance.

U.S. FDA to Roll Out AI Tools Across All Centers Following Successful Pilot

/in /tarafından

The U.S. Food and Drug Administration (FDA) announced it will immediately begin deploying artificial intelligence tools internally across all of its centers, with full integration expected by June 30. The move follows a successful generative AI pilot aimed at supporting scientific reviewers in accelerating the drug review process.

WHY IT MATTERS:
The FDA typically has 6 to 10 months to evaluate a drug approval application. The newly tested generative AI tools are designed to ease the burden on scientists by automating repetitive and time-consuming tasks, thereby streamlining the overall review process and potentially speeding up access to life-saving treatments.

In a statement, the agency emphasized that the focus of future AI enhancements would be on usability, better document integration, and center-specific output customization — all while upholding strict data security and FDA compliance standards.

KEY QUOTE:
“Future enhancements will focus on improving usability, expanding document integration and tailoring outputs to center-specific needs, while maintaining strict information security and compliance with FDA policy,” the FDA said.

CONTEXT:
The announcement comes just a day after Wired reported that the FDA had been in discussions with OpenAI, the maker of ChatGPT, regarding potential AI collaborations. The report also mentioned that representatives from Elon Musk’s Department of Government Efficiency had attended multiple meetings with both the FDA and OpenAI in recent weeks.

WHAT’S NEXT:
The FDA plans to monitor the system’s performance closely, solicit feedback from its users, and refine the tools accordingly. The agency has committed to releasing more information about the AI implementation and its outcomes in June.

This marks one of the most significant government-level adoptions of generative AI to date and could signal a broader shift toward AI-assisted regulatory workflows in the healthcare and pharmaceutical sectors.